Markets:

Overview

News

Currencies

International

Treasuries

NewAmsterdam Pharma Company N.V. - Ordinary Shares (NQ:NAMS)

19.46 -0.25 (-1.24%)

Delayed Quote Updated: 10:20 AM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about NewAmsterdam Pharma Company N.V. - Ordinary Shares

< Previous 1 2 3 Next >

Curious about the stocks that are showing activity after the closing bell on Monday? ↗

September 07, 2026

Via Chartmill

Stay updated with the stocks that are on the move in today's after-hours session. ↗

September 04, 2026

Via Chartmill

NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears ↗

August 05, 2026

NewAmsterdam Pharma (NASDAQ:NAMS) used its annual Investor Day to outline its cardiovascular outcomes strategy for obicetrapib, provide updates on additional clinical programs and discuss commercial...

Via MarketBeat

Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗

May 30, 2026

This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors.

Via The Motley Fool

NewAmsterdam Pharma (NASDAQ:NAMS) Beats Q1 Revenue and EPS Estimates as Key Trial Catalysts Loom ↗

May 07, 2026

Via Chartmill

7 Analysts Have This To Say About NewAmsterdam Pharma ↗

February 27, 2025

Via Benzinga

Deep Dive Into NewAmsterdam Pharma Stock: Analyst Perspectives (8 Ratings) ↗

January 24, 2025

Via Benzinga

Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗

May 30, 2026

Dyne Therapeutics targets rare muscle diseases with its FORCE platform, aiming to meet unmet needs in neuromuscular therapeutics.

Via The Motley Fool

NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends ↗

May 08, 2026

NewAmsterdam Pharma (NASDAQ:NAMS) said it plans to conduct an interim analysis of its ongoing PREVAIL cardiovascular outcomes trial (CVOT) for obicetrapib in the fourth quarter of 2026, citing what...

Via MarketBeat

This Biotech Was Quietly Bought Before a $58 Per Share Takeout ↗

March 21, 2026

This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in active trials.

Via The Motley Fool

Where NewAmsterdam Pharma Stands With Analysts ↗

December 30, 2024

Via Benzinga

Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million ↗

November 20, 2025

Bain Capital added more than 12.4 million shares of HeartFlow stock in the thrid quarter

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer ↗

November 20, 2025

Bain Capital's bet on Cidara Therapeutics stocks has paid off in a big way

Via The Motley Fool

Topics Regulatory Compliance

Biotech Stock Gets Booted in Latest Fund Update ↗

November 19, 2025

Bain Capital sold its entire stake in Nuvalent stock during the third quarter.

Via The Motley Fool

Topics Regulatory Compliance

Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock ↗

November 19, 2025

Bain Capital completely exited its position in Disc Medicine stock during the third quarter

Via The Motley Fool

Why Bain Capital Is Selling Shares of This Biotech Stock Now ↗

November 18, 2025

Bain Capital sold $20 million worth of Pharvaris stock during the third quarter.

Via The Motley Fool

Topics Regulatory Compliance

Deep Dive Into NewAmsterdam Pharma Co Stock: Analyst Perspectives (4 Ratings) ↗

October 20, 2025

Via Benzinga

Expert Outlook: NewAmsterdam Pharma Co Through The Eyes Of 6 Analysts ↗

August 25, 2025

Via Benzinga

What 5 Analyst Ratings Have To Say About NewAmsterdam Pharma Co ↗

August 07, 2025

Via Benzinga

NewAmsterdam (NAMS) Q2 Revenue Jumps 49% ↗

August 06, 2025

Via The Motley Fool

What Analysts Are Saying About NewAmsterdam Pharma Co Stock ↗

June 12, 2025

Via Benzinga

Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib ↗

June 09, 2025

NewAmsterdam shared new Phase 3 data showing obicetrapib reduced LDL-C by 33% and impacted Alzheimer's biomarkers ahead of July 2025 presentation.

Via Benzinga

Get insights into the top gainers and losers of Monday's pre-market session. ↗

June 09, 2025

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

April 22, 2025

Via Benzinga

The Analyst Verdict: NewAmsterdam Pharma Co In The Eyes Of 6 Experts ↗

April 08, 2025

Via Benzinga

Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol? ↗

March 31, 2025

The company unveiled promising results for its experimental cholesterol treatment, a daily pill that blocks PCSK9.

Via Investor's Business Daily

Flywire Posts Downbeat Results, Joins Lemonade, Ginkgo Bioworks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

February 26, 2025

Via Benzinga

Why ZoomInfo Technologies Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket ↗

February 26, 2025

Via Benzinga

Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

January 16, 2025

Via Benzinga

Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio? ↗

December 15, 2024

These 10 mid-cap stocks performed well last week. Are they in your portfolio? PDCO, NAMS, WBA, NVCR, RH, PTVE, CRK, RNW, ALK, STVN.

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.